# DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positi

Source: https://onco.cc/trials/nct07440290/  
OnCo record `nct07440290` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of dabrafenib and trametinib in pancreatic cancer, run by Cancer Research UK, now recruiting.

## Summary

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. is a phase 2/3, interventional study registered as NCT07440290 by Cancer Research UK, with a registry enrolment figure of 30 participants, started 2026-04-01 and due to reach its primary completion in 2029-10. Interventions recorded: Dabrafenib; Trametinib. Conditions listed: Haematological Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Gastrointestinal Cancer; Non-Melanoma Skin Cancer (NMSC); Langerhans Cell Histiocytosis (LCH); Cancer; Erdheim-Chester Disease; Thyroid Carcinoma, Papillary; Ovarian Neoplasms; Colorectal Neoplasms; Laryngeal Neoplasms; Carcinoma, Non-Small Cell-Lung; Glioma; Multiple Myeloma; Thyroid Carcinoma, Anaplastic; Solid Tumour; Pancreatic Diseases. Primary outcome: Objective response (OR); Durable Clinical Benefit (DCB). Sites: United Kingdom. United Kingdom sites listed: 27. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: DETERMINE
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07440290
- Phase: 2/3
- Setting: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations.
- Sponsor: Cancer Research UK
- Enrolled: 30

## Notes

- UK sites (registry): Belfast City Hospital (Belfast); University Hospital Birmingham (Birmingham); Birmingham Children's Hospital (Birmingham); Bristol Royal Hospital for Children (Bristol); Bristol Haematology and Oncology Centre (Bristol); Addenbrooke's Hospital (Cambridge); Velindre Cancer Centre (Cardiff); Cardiff Children's Hospital (Cardiff); Western General Hospital (Edinburgh); The Beatson Hospital (Glasgow); Royal Hospital for Children Glasgow (Glasgow); Leicester Royal Infirmary (Leicester) and 15 more.

## Sources

- ClinicalTrials.gov NCT07440290: https://clinicaltrials.gov/study/NCT07440290

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Dabrafenib](https://onco.cc/drugs/dabrafenib/), [Trametinib](https://onco.cc/drugs/trametinib/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07440290.json